Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Sep;36(9):1837–1842. doi: 10.1128/aac.36.9.1837

Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine.

D F Smee 1, J L Morris 1, J A Leonhardt 1, J R Mead 1, A Holy 1, R W Sidwell 1
PMCID: PMC192196  PMID: 1329629

Abstract

Severe combined immunodeficient (SCID) mice were found to be highly susceptible to murine cytomegalovirus (MCMV) infection. Treatment of infected mice with ganciclovir (12.5, 25, and 50 mg/kg of body weight for 10 days) starting 24 h after virus challenge resulted in delays in death by 2 to 8 days, and no animals survived the infection. (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine (HPMPC) was much more potent, with doses of 1, 3.2, and 10 mg/kg/day (for 10 days) increasing the mean survival time by 15 to 30 days. Twenty-day treatments with HPMPC starting 5 days after virus inoculation increased the mean survival time by 24 to 32 days, with once-weekly (50-mg/kg) treatments being equivalent to daily (10-mg/kg) treatments. Delays in the development of liver, lung, and spleen virus titers in ganciclovir- and HPMPC-treated groups correlated with extensions in the mean survival times relative to the survival times of the placebo controls. The two compounds were approximately equally toxic to uninfected BALB/c mice treated for 10 days, causing 80 to 100% mortality after a dose of 150 mg/kg and 0% mortality after a dose of 75 mg/kg. Thus, the relative therapeutic index of HPMPC was 50-fold greater than that of ganciclovir. Recombinant alpha interferon delta 4 alpha 1/alpha 2 (1 x 10(4) and 5 x 10(4) units per mouse per day) and bropirimine (100 and 300 mg/kg/day) provided no protection from the lethal MCMV infection. The severe combined immunodeficient mouse MCMV infection is an important new model that will permit chemotherapy regimens to be studied over several months.

Full text

PDF
1837

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brideau R. J., Nicholas J. A. Pyrimidinone (bropirimine) mediated alteration of T lymphocyte subsets during murine cytomegalovirus infection. Clin Exp Immunol. 1987 Jun;68(3):613–620. [PMC free article] [PubMed] [Google Scholar]
  2. Brideau R. J., Wolcott J. A. Effect of pyrimidinone treatment on lethal and immunosuppressive murine cytomegalovirus infection. Antimicrob Agents Chemother. 1985 Oct;28(4):485–488. doi: 10.1128/aac.28.4.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Browne M. J., Moss M. Y., Boyd M. R. Comparative activity of amantadine and ribavirin against influenza virus in vitro: possible clinical relevance. Antimicrob Agents Chemother. 1983 Mar;23(3):503–505. doi: 10.1128/aac.23.3.503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chong K. T., Gresser I., Mims C. A. Interferon as a defence mechanism in mouse cytomegalovirus infection. J Gen Virol. 1983 Feb;64(Pt 2):461–464. doi: 10.1099/0022-1317-64-2-461. [DOI] [PubMed] [Google Scholar]
  5. De Castro L. M., Kern E. R., De Clercq E., Ghaffar A., Mayer E. P., Vogt P. E., Gangemi J. D. Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. Antiviral Res. 1991 Jul;16(1):101–114. doi: 10.1016/0166-3542(91)90062-v. [DOI] [PubMed] [Google Scholar]
  6. Erice A., Chou S., Biron K. K., Stanat S. C., Balfour H. H., Jr, Jordan M. C. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med. 1989 Feb 2;320(5):289–293. doi: 10.1056/NEJM198902023200505. [DOI] [PubMed] [Google Scholar]
  7. Fish E. N., Banerjee K., Levine H. L., Stebbing N. Antiherpetic effects of a human alpha interferon analog, IFN-alpha Con1, in hamsters. Antimicrob Agents Chemother. 1986 Jul;30(1):52–56. doi: 10.1128/aac.30.1.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Grundy J. E., Trapman J., Allan J. E., Shellam G. R., Melief C. J. Evidence for a protective role of interferon in resistance to murine cytomegalovirus and its control by non-H-2-linked genes. Infect Immun. 1982 Jul;37(1):143–150. doi: 10.1128/iai.37.1.143-150.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hudson J. B. The murine cytomegalovirus as a model for the study of viral pathogenesis and persistent infections. Arch Virol. 1979;62(1):1–29. doi: 10.1007/BF01314900. [DOI] [PubMed] [Google Scholar]
  10. Kern E. R. Value of animal models to evaluate agents with potential activity against human cytomegalovirus. Transplant Proc. 1991 Jun;23(3 Suppl 3):152-5, discussion 155. [PubMed] [Google Scholar]
  11. Laskin O. L., Cederberg D. M., Mills J., Eron L. J., Mildvan D., Spector S. A. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med. 1987 Aug;83(2):201–207. doi: 10.1016/0002-9343(87)90685-1. [DOI] [PubMed] [Google Scholar]
  12. McCune J. M., Namikawa R., Kaneshima H., Shultz L. D., Lieberman M., Weissman I. L. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science. 1988 Sep 23;241(4873):1632–1639. doi: 10.1126/science.241.4873.1632. [DOI] [PubMed] [Google Scholar]
  13. Neyts J., Balzarini J., Naesens L., De Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice. J Med Virol. 1992 May;37(1):67–71. doi: 10.1002/jmv.1890370112. [DOI] [PubMed] [Google Scholar]
  14. Richard K. A., Mortensen R. F., Tracey D. E. Cytokines involved in the augmentation of murine natural killer cell activity by pyrimidinones in vivo. J Biol Response Mod. 1987 Dec;6(6):647–663. [PubMed] [Google Scholar]
  15. Rubin R. H. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis. 1990 Sep-Oct;12 (Suppl 7):S754–S766. doi: 10.1093/clinids/12.supplement_7.s754. [DOI] [PubMed] [Google Scholar]
  16. Rubin R. H., Lynch P., Pasternack M. S., Schoenfeld D., Medearis D. N., Jr Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice. Antimicrob Agents Chemother. 1989 Nov;33(11):1975–1979. doi: 10.1128/aac.33.11.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Schooley R. T. Cytomegalovirus in the setting of infection with human immunodeficiency virus. Rev Infect Dis. 1990 Sep-Oct;12 (Suppl 7):S811–S819. doi: 10.1093/clinids/12.supplement_7.s811. [DOI] [PubMed] [Google Scholar]
  18. Selgrade M. K., Ahmed A., Sell K. W., Gershwin M. E., Steinberg A. D. Effect of murine cytomegalovirus on the in vitro responses of T and B cells to mitogens. J Immunol. 1976 May;116(5):1459–1465. [PubMed] [Google Scholar]
  19. Shanley J. D., Pesanti E. L. The relation of viral replication to interstitial pneumonitis in murine cytomegalovirus lung infection. J Infect Dis. 1985 Mar;151(3):454–458. doi: 10.1093/infdis/151.3.454. [DOI] [PubMed] [Google Scholar]
  20. Shultz L. D., Sidman C. L. Genetically determined murine models of immunodeficiency. Annu Rev Immunol. 1987;5:367–403. doi: 10.1146/annurev.iy.05.040187.002055. [DOI] [PubMed] [Google Scholar]
  21. Smee D. F., Alaghamandan H. A., Jin A., Sharma B. S., Jolley W. B. Roles of interferon and natural killer cells in the antiviral activity of 7-thia-8-oxoguanosine against Semliki Forest virus infections in mice. Antiviral Res. 1990 Feb;13(2):91–102. doi: 10.1016/0166-3542(90)90025-3. [DOI] [PubMed] [Google Scholar]
  22. Smee D. F., Burger R. A., Coombs J., Huffman J. H., Sidwell R. W. Progressive murine cytomegalovirus disease after termination of ganciclovir therapy in mice immunosuppressed by cyclophosphamide treatment. J Infect Dis. 1991 Nov;164(5):958–961. doi: 10.1093/infdis/164.5.958. [DOI] [PubMed] [Google Scholar]
  23. Smee D. F., Colletti A., Alaghamandan H. A., Allen L. B. Evaluation of continuous cell lines in antiviral studies with murine cytomegalovirus. Arch Virol. 1989;107(3-4):253–260. doi: 10.1007/BF01317921. [DOI] [PubMed] [Google Scholar]
  24. Snoeck R., Sakuma T., De Clercq E., Rosenberg I., Holy A. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother. 1988 Dec;32(12):1839–1844. doi: 10.1128/aac.32.12.1839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Stringfellow D. A., Weed S. D., Underwood G. E. Antiviral and interferon-inducing properties of 1,5-diamino anthraquinones. Antimicrob Agents Chemother. 1979 Jan;15(1):111–118. doi: 10.1128/aac.15.1.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Walmsley S. L., Chew E., Read S. E., Vellend H., Salit I., Rachlis A., Fanning M. M. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet). J Infect Dis. 1988 Mar;157(3):569–572. doi: 10.1093/infdis/157.3.569. [DOI] [PubMed] [Google Scholar]
  27. Welsh R. M. Regulation of virus infections by natural killer cells. A review. Nat Immun Cell Growth Regul. 1986;5(4):169–199. [PubMed] [Google Scholar]
  28. Yang H., Datema R. Prolonged and potent therapeutic and prophylactic effects of (S)-1-[(3-hydroxy-2-phosphonylmethoxy)propyl]cytosine against herpes simplex virus type 2 infections in mice. Antimicrob Agents Chemother. 1991 Aug;35(8):1596–1600. doi: 10.1128/aac.35.8.1596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Yow M. D. Congenital cytomegalovirus disease: a NOW problem. J Infect Dis. 1989 Feb;159(2):163–167. doi: 10.1093/infdis/159.2.163. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES